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Abstract
Background and Methods: To understand the burden and epidemiology of Streptococcus pneumoniae disease among children
between 1 and 59 months of age in China, we conducted a review of literature published between 1980 and 2008 applying
standardized algorithms. Because of the absence of population-based surveillance for pneumococcal disease (PD), we identified
all-cause pneumonia, bacteremia and meningitis burden, syndromes most commonly associated with S. pneumoniae, and applied
the proportion of disease attributable to S. pneumoniae from studies that determined the etiology of these three syndromes to
calculate PD burden. Because of the microbiologic difficulties in identifying S. pneumoniae–attributable pneumonia which likely
underestimates the pneumonia burden, we also used the proportion obtained from vaccine efficacy trials.
Results: Between 1980 and 2008, there were 12,815 cases/100,000/year of all-cause pneumonia among children between 1
month and 59 months, with 526 deaths/100,000 annually. There were 14 meningitis cases/100,000/year. We estimate that as
of 2000, there were 260,768 (113,000 to 582,382) and 902 (114–4,463) cases of pneumococcal pneumonia and meningitis,
respectively with 10,703 (4,638–23,904) and 75 (9–370) pneumococcal pneumonia and meningitis deaths, respectively.
Pneumococcal pneumonia cases and deaths were more than two-fold higher, 695,382 (173,845–1,216,918) and 28,542
(7,136–49,949), respectively, when parameters from efficacy trials were used. Serotypes 19F, 19A and 14 were the most
common serotypes obtained from pneumonia/meningitis patients. Currently available vaccines are expected to cover 79.5%
to 88.4% of the prevalent serotypes. With high antibiotic resistance, introducing pneumococcal vaccines to the routine
immunization program should be considered in China. Population-based studies are warranted.
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Introduction
Pneumococcal disease (PD) is the leading cause of vaccine-
preventable deaths worldwide [1] accounting for ,800,000 deaths
annually among children ,5 years of age [2,3,4]. The disease
caused by Streptococcus pneumoniae, may be invasive resulting in high
case-fatality rates of 5% to 20% and 40% to 50% for bacteremia
and meningitis, respectively, and in long-term sequelae [5,6,7]. PD
may also be non-invasive such as pneumonia where majority of the
burden lie considering that ,50% of severe pneumonia is believed
to be pneumococcal in etiology (2). However, due to technical
difficulties, limitations in access to care and prior antimicrobial
use, estimating PD burden remains challenging [8,9].
Widespread use of pneumococcal conjugate vaccines (PCV) in
infants and children resulted in substantial declines in invasive PD
(IPD), pneumonia, and otitis media [10,11,12,13,14]. However,
most countries in Asia, including China have not adopted PCVs in
their national immunization schedules due to a multitude of
reasons including costs, logistic difficulties in introducing a new
vaccine and paucity of disease burden data. The limited serotype
coverage of PCV7 was also a disincentive in some countries to
introduce the vaccine.
Little is known regarding the burden of S. pneumoniae-related
diseases and the predominant serotypes causing disease in China
[15]. Because the distribution of pneumococcal serotypes vary
with age, geographic region and time [16], it is crucial to ascertain
the circulating pneumococcal serotypes and the corresponding
coverage of available pneumococcal conjugate vaccines [17]. This
comprehensive systematic review of available English and Chinese
literature of studies conducted between 1980 and 2008 aimed to
PLoS ONE | www.plosone.org 1 November 2011 | Volume 6 | Issue 11 | e27333identify the disease burden and serotype distribution of pneumo-
coccal disease in children under 5 years of age in China. A
complete understanding of the pneumococcus-associated disease
burden in China is critical for developing evidence-based disease
burden estimates upon which control measures such as immuni-
zation may be based.
Methods
No population based study determining the burden of
pneumococcal disease has been conducted in China, therefore
we first, determined the burden of all-cause pneumonia,
bacteremia and meningitis, three syndromes most commonly
associated with S. pneumoniae. Since disease rates may be
underestimated when children do not reach the health care
facilities, some studies may present incidence rates adjusted for the
proportion of missed cases. These adjusted rates were considered
whenever they were reported.
Next, from studies that determined the etiology of these three
syndromes, we obtained the proportion of disease attributable to S.
pneumoniae. By applying these proportions to the burden of all-
cause pneumonia, bacteremia and meningitis, estimates of
pneumococcal pneumonia, bacteremia and meningitis were
obtained. For bacteremia and meningitis, culture positive blood
or CSF specimens were considered sufficiently sensitive to provide
relatively precise estimates of disease burden. However, for
pneumonia, the proportion we obtained from microbiologic
studies may not be sensitive enough to ascertain the true
proportion of pneumonia attributable to S. pneumoniae and is more
likely an underestimate of the true burden. Thus, we also used the
efficacy estimate for WHO-defined clinical pneumonia as
previously reported by O’Brien et al. [4]. This proportion was
then applied to all-cause pneumonia estimates from this review to
obtain pneumococcal pneumonia burden.
Search strategy
Studies on pneumonia, meningitis and bacteremia caused by S.
pneumoniae, published between 1980 and 2008, were identified
using standardized search algorithms for systematic reviews [18].
Scientific articles published in English and Chinese languages were
sought through searching PubMed (United States), Ovid online
(United States), SinoMed (Chinese Bio-Medical Literature Service
System, China), CNKI (National Knowledge Infrastructure,
China) databases. Standardized medical subject heading (MeSH)
terms: Meningitis, Bacterial; Pneumonia; Bacteremia; Pneumonia,
Pneumococcal; Streptococcus pneumoniae, and Free words: China,
were established for searching.
Prior to the literature search, a pilot study was conducted to
refine the MeSH terms and combinations thereof, especially when
the terms were translated to Chinese, prior to searching non-
English electronic databases.
Definitions
Cases of meningitis were defined as having signs of meningeal
inflammation with or without isolation of bacterial pathogen.
Bacteremia was defined as the presence of pathogenic organisms
in the bloodstream. Because of the expected heterogeneity in the
definition of pneumonia among the Chinese studies, a more
inclusive definition for pneumonia was used to estimate the
proportion of all- cause pneumonia episodes that were pneumo-
coccal in etiology. The studies used the following definitions for
pneumonia: (1) WHO definition for clinical pneumonia [19], (2)
Respiratory Society of the Chinese Medical Association commu-
nity acquired pneumonia guidelines for diagnosis and treatment
(Defined as the presence of a new infiltration on chest radiographs
and at least one of the following: documentation of a new cough
with or without sputum production or exacerbation of chronic
respiratory diseases with purulent sputum production with or
without chest pain; documented fever (37.3uC); auscultatory
findings on pulmonary examination and/or evidence of pulmo-
nary consolidation; and white blood cells (WBC) count.10610
9/
L or leucopenia (WBC,4610
9/L) [20]. and (3) physicians’
assessment with or without radiologic findings.
Review strategy
EndnoteH (version X, Thomson, Inc., Philadelphia, U.S.A.)
bibliographic software was used to create an electronic library of
citations identified in the database searches. PubMed searches
were performed using EndnoteH and duplicate records were
deleted. For articles published in Chinese and English, if identical
data were presented, the English language article was used. Each
study was assigned a unique identification code to enable tracking
of reviews and analysis after title/abstract screening. Eight
reviewers trained to perform the title/abstract screening and
thereafter full text screening were assigned into two groups. The
inter-reviewer agreements were calculated and kappa values were
presented. Appraisal of quality based on the study design, patient
recruitment, case definitions and diagnostic methods, was
performed for those articles that fulfilled the inclusion criteria
using a structured questionnaire. In order to identify the
differences in homogeneity of the published articles, each question
was assigned a score, with 0 being the lowest and 5 being the
highest. Mean points per question were calculated for each article.
Articles with $3.0 points/question were assigned to moderate/
high quality. A structured questionnaire was used for data
extraction, and the EpiData (version 3.1) program was used for
data entry.
Study inclusion and exclusion criteria
All studies published from 1980 to 2008 in English and non-
English languages, obtained from the sources defined above were
assessed.
Studies had to fulfill the following criteria to be included: 1)
include children between 1 month and 5 years of age; 2)
conducted in mainland China; 3) has extractable data on
pneumonia, meningitis and bacteremia; 4) did not exclusively
pertain to clinical diagnostic methods, purified basic research,
therapies, case reports (single case), health education, policy
analysis and case-control studies; 5) conducted after 1980 or
disaggregation allows to identify cases after 1980; 6) the
surveillance period was at least 12 months 7) were laboratory-
based studies on the different etiologic agents with #100
pathogens or if the study is on antimicrobial resistance of S.
pneumoniae had #50 isolates.
Analytical strategy and statistical analysis
SAS statistical software was used for analysis (SAS Institute Inc.,
Cary, North Carolina, USA). PD burden was estimated through
multiplying the proportions of pneumonia, meningitis and
bacteremia caused by S. pneumoniae with the mortality and
morbidity of pneumonia, meningitis and bacteremia, using the
data summarized from this review, and 2000 national census. For
pneumonia, we also applied the proportion obtained by O’Brien
et al. [4]. For overall mortality, morbidity, and antimicrobial
resistance, the pooled average from all studies and high quality
articles (mean score per question $3.0) were calculated.
To pool data from available studies, meta-analysis with random-
effects model was performed to calculate the point estimate and
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mation of individual proportion or rate. If zero events occurred, a
correction factor of 0.5 was applied. When the number of original
studies was less than four, meta-analysis with random-effects
model was only conducted to obtain an average estimate; the 95%
CI was presented accordingly [21,22,23,24]. To assess differences
in geographic regions, poison regression was used.
Ethics
This study was reviewed and approved by the Institutes of
Biomedical Sciences Institutional Review Board, Fudan Univer-
sity.
Results
Overview of studies
The initial search identified 70,838 pneumonia-, meningitis-
and bacteremia-related citations. After exclusion of duplicate
records, 65,836 and 3,621 studies were excluded following review
of title/abstract and full text information, respectively (Figure 1).
The inter-observer agreement was 85% and 57% (P 0.05) for title/
abstract and full text screen, respectively. Forty-nine published
studies met the inclusion and exclusion criteria for this review and
were included in the final analysis. Of these, only three (6.1%)
studies were published in English. After quality assessment, 95.9%
(n=47) studies were labeled with higher mean score ($3.0/
questions). For all-cause pneumonia-, meningitis- and bacteremia-
related citations, 42.9% (n=21) were hospital-based, 30.6%
(n=15) were community-based and 26.5% (n=13) laboratory-
based surveillance. Out of 12 studies reporting on all-cause
pneumonia burden, three used the WHO definition of pneumo-
nia, five used the Chinese Medical Association guidelines. and four
were based on physicians’ diagnoses. Majority of the studies were
from the eastern provinces (n=28, 57.1%), followed by the central
provinces (n=10, 20.4%) and the western provinces (n=6,
12.2%). 41 articles presented the results of antimicrobial resistance
Figure 1. Eligibility of studies for inclusion in systematic review, China.
doi:10.1371/journal.pone.0027333.g001
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whereas 43.9% (n=18) reported the minimum inhibitory
concentration (MIC). Data on S. pneumoniae bacteremia unrelated
to pneumonia or to meningitis were not available.
Morbidity, mortality and CFR of all-cause pneumonia and
meningitis
Between 1980 and 2008, the occurrence of all-cause pneumonia
among children aged between 1 month and 59 months was
12,815/100,000/year (95% CI: 8625–18623/100,000/year) with
a mortality rate of 526/100,000/year (95% CI: 262/100,000/
year–1053/100,000/year) (Table 1, Figure 2, Figure 3). Among
the 12 papers that reported on pneumonia incidence, 10 used a
clinical definition of pneumonia and two papers used radiologic
and/or clinical diagnosis. The addition of the two papers did not
alter the results of pneumonia incidence (data not shown).
There were 14 meningitis cases/100,000/year (95% CI: 0.1-
1579.4/100,000/year). Regardless of the study year, similar
pneumonia morbidity rates were found in eastern and western
provinces, and lowest in central provinces (p=0.009), while
mortality rates in the three regions were not significantly different.
Proportion of S. pneumoniae infections and
nasopharyngeal carriage of S. pneumoniae among ill
children ,5 years of age
Out of five studies with 971 CSF culture specimens from meningitis
cases, 142 S. pneumoniae were identified (pooled percentage 9.5%, 95%
CI 1.2–47.1). Nine studies reported 9,579 specimens from tracheal
aspirates, bronchoalveolar lavage, pleural fluid and lung puncture
from patients presenting to the hospital with pneumonia, among
which 502 specimens yielded S. pneumoniae (pooled percentage 3%,
95% CI, 1.3–6.7). Two studies with 1,455 nasopharyngeal swabs from
patients presenting with pneumonia or meningitis had 387 S.
pneumoniae identified (pooled percentage 27%, 95% CI 25.8–29.2).
Distribution of serotypes from ill children ,5 years of age
Only one out of four papers that reported on serotype
distribution presented results from invasive specimens separately.
The most common serotypes among invasive isolates were 19A
(29%), 19F (22.5%) and 14 (12.9%). These serotypes were also
among the top five most commonly identified serotypes from
mixed specimens, namely: 19F (35.7–70.9%), 19A (9.7–11.8%),
23F (5.8–24.1%), 6B (5.1–7.3%) and 14 (2.9–7.8%) (Table 2). Our
findings show that the putative coverage of the 7–10- and 13-
valent pneumococcal conjugate vaccines were 79.5% (95%CI:
47.9–94.3%), 79.7% (95%CI: 48.5–94.2%) and 87.2% (95%CI:
65.0–96.1%), respectively of isolates from mixed specimens.
Profile of antimicrobial resistance
Twenty articles reported on antimicrobial resistance. Of these,
three articles included results from invasive isolates but the results
cannot be disaggregated and 17 studies (85%) reported on
nasopharyngeal swabs from ill patients or sputum specimens. All
the articles included in this review used the old Clinical and
Laboratory Standards Institute (CLSI) breakpoint for penicillin
resistance [25] and reported as such. Regardless of study quality,
the articles reported high rates of antimicrobial resistance (Table 3).
There was a trend towards increasing antimicrobial resistance for
erythromycin (44.2, 95%CI: 0–80.1 vs 84.1, 95% CI: 71.2–91.9)
and penicillin (11.5, 95%CI: 0–11.5 vs 16.1, 95%CI: 8.2–29.2)
between 1990–1999 and 2000–2008, although these were not
statistically significant. One article reported 100% resistance to
azithromycin while another article reported susceptibility to
vancomycin was 76.6% (95%CI: 0–100).
Estimates of the burden for S. pneumoniae-specific –
pneumonia and -meningitis
Using the 2000 China census data of 67,828,891 children ,5
years of age and the parameters obtained in our review, we
estimate that there were 260,768 (113,000–582,382) pneumonia
and 902 (114–4,463) meningitis cases caused by S. pneumoniae.
Furthermore, the estimated deaths due to S. pneumoniae pneumonia
and meningitis were 10,703 (4,638–23,904) and 75 (10–370),
respectively. Applying the proportions obtained by O’Brien et al.
for pneumonia, we estimate that there were 695,382 (173,845–
1,216,918) pneumococcal pneumonia cases and 28,542 (7,136–
Table 1. Mortality, morbidity, and case-fatality rate due to pneumonia, meningitis and bacteremia, 1980–2008
a,b,c.
Disease Morbidity Mortality Case-fatality
Rate (n
d) 95%CI Rate (n) 95%CI Rate (n) 95%CI
Pneumonia by year (n=12)
1980–1989 6935.6(3) 4775.6, 9444.9, 7305.9
e 520.2(3) 187.4, 479.9, 1565.6
e 1.4(2) 2.0, 1.0
e
1990–1999 14210.9(8) 8663.1–22438.6 551.4(8) 237.8–1273.7 1.3(2) 1.4,0.9
e
Overall 12815(10) 8625–18623 526(10) 262–1053 1.4(4) 0.7–2.5
Pneumonia by region (n=10)
Eastern provinces 18807.0(3) 22203.2,12909.1,22701.8
e 577.9(3) 1364.7, 71.2, 700.8 - -
Central provinces 8370.6(4)
f 3323.2–19535.2 623.8(3) 1263.8, 151.6, 1158.1 1.4(1) -
Western provinces 18347.9(2) 19377.8, 17700.1
e 574.9(2) 178.1, 1469.9 0.9(1) -
Meningitis (n=4)
Overall 14(2) 8.9, 19.2
e - - 8.3(3) 18.4, 9.1, 2.5
e
aMortality and morbidity were expressed as 1/100,000/year; case-fatality rate was expressed as percentages.
bThe mean score per question of all articles was $3.0.
cthe Ministry of Health-defined geographic-economic strata, which was applied in the 4th national health survey in 2005 [47] was implemented.
dn represents the number of articles.
eNumbers presented are from the original publication.
fCompared to Eastern and Western province, poisson regression, p,0.05.
doi:10.1371/journal.pone.0027333.t001
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years of age in 2000 in Mainland China. (Table 4).
Discussion
Our study confirms that pneumococcal disease is a significant
health problem among children ,5 years in China. Using the
parameters that we obtained in our study, our estimates are
somewhat lower than the 30,000 pneumococcal deaths estimated
by O’Brien et al. [4], using different methodology, different
population figures and included few studies from China. We
believe that the pneumonia burden using the proportionality that
we obtained from our review is an underestimate of the true
pneumococcal pneumonia burden because of the difficulties
encountered in identifying the proportion of pneumonia due to
S. pneumoniae microbiologically. Thus, we also used proportions
obtained by O’Brien et al from vaccine efficacy trials. By applying
these proportions, pneumococcal pneumonia cases and deaths
increased by more than two-fold. Our results were based on a
systematic review of mostly prospective, community or hospital
based studies. When compared with the results obtained by
Rudan, et al., using the Chinese Maternal and Child Mortality
Surveillance (MCMS) system, we found that our estimates were
somewhat lower. Assuming that 50% of all pneumonia deaths in
2000 were attributed to S. pneumoniae, our estimates for
pneumococcal pneumonia deaths, using microbiologic and
O’Brien’s parameters were conservative.
There are inherent difficulties encountered in conducting
studies assessing disease burden which likely underestimates the
true burden in developing countries. First, disease is often
underestimated when children do not reach the health facilities
where surveillance is being conducted for case ascertainment. In
Figure 2. Forest plot of pneumonia morbidity.
doi:10.1371/journal.pone.0027333.g002
Figure 3. Forest plot of pneumonia mortality.
doi:10.1371/journal.pone.0027333.g003
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for these missed cases. Second, in assessing the number of deaths
due to pneumococcal pneumonia, we did not adjust for S.
pneumoniae being more likely associated with severe and fatal
disease. Rudan, et al, estimated that there were 22 million episodes
of pneumonia in Chinese children aged ,5 years of age in 2000
and that 30–50% of radiological and fatal pneumonia were due to
S. pneumoniae [26]. In Beijing, 55% of children aged 1 month to 5
years who died of community-acquired pneumonia had S.
pneumoniae identified in their lung tissues using newer microbiologic
techniques such as in situ PCR and/or Southern blotting [27].
Third, the hospital-based studies determining etiologies of
pneumonia and meningitis which were included in this analysis
were mostly conducted in tertiary hospitals, where patients were
likely more severe and thus may not be representative of the
spectrum of diseases in the population. Studies in Bangladesh
demonstrated that compared with hospital-based designs, more S.
pneumoniae cases can be identified through community-based
studies [28,29]. Fourth, the overuse of antibiotics in the early
stage of illness could lower the culture positivity rate. In Asia,
where antibiotics are readily available without prescriptions, a
study conducted in China revealed high prior antibiotic usage
among patients presenting in city/county hospitals, township
hospitals and clinics at 96.6%, 88.0% and 78.6% respectively [30].
In a bacteremia surveillance in Thailand conducted in 2005–2006,
it was estimated that prior antibiotic use reduced pneumococcal
bacteremia incidence by 32% overall and 39% in children ,5
years of age [31]. While other modalities such as antigen detection
have been used in identifying pneumococcal infection and resulted
in higher incidence rates [32,33], culture remains to be the gold
standard in detecting pneumococcal infections.
Certain limitations were specific to our study. First, we included
studies with substantial differences in quality. Nonetheless, after
stratifying by the quality of articles, no notable difference in
parameters between those pooled from high quality studies and all
studies in general (which could make the conclusion towards the
opposite direction), was observed. Furthermore, precise numbers
may not be as important as the patterns and trends emerging from
the analysis. Second, we only included the three syndromes most
commonly associated with S. pneumoniae and we have missed on
other diseases associated with this disease, contributing further to
the underestimation of the PD burden. Moreover, non-standard-
ized definitions of pneumonia were used in some studies which
may have further affected our estimates. Third, most of the studies
combined reports from invasive and non-invasive isolates for
serotyping and antimicrobial resistance, limiting our ability to
predict serotype coverage and the potential for preventing
antimicrobial resistance by PCVs against IPD. Lastly, we included
data from studies conducted .20 years ago to calculate PD
burden. This allowed inclusion of studies with substantial
heterogeneity as laboratory procedures and diagnostic capabilities
may have changed. Comparison of data thru time showed an
increased occurrence of pneumonia in the 1990 s compared to the
1980 s, with no change in mortality. Moreover, the substantial
economic development in China in the past 20 years may have
lead to changes in sanitation, living conditions and access to health
Table 2. Serotype distribution of S. pneumoniae isolates from patients with pneumonia, meningitis and bacteremia
a.
Studies (Publication Year)
Zhao GM, et al. 2003
Liu Y, et al.
2008 Deng Q, et al. 2008
Yao KH, et al.
2008
Specimen type Sputum
Sputum, purulent
discharge Blood, CSF, Pleural fluid Sputum
Hypopharyngeal
aspirates
Serotype n % n % n % n % n %
4 -- - - - - 2 2.5 8 2.9
6B 6 5.4 33 7.9 - - 4 5.1 15 5.4
14 8 7.1 31 7.4 4 12.9 - - 8 2.9
19F 40 35.7 183 43.5 7 22.5 56 70.9 169 60.6
23F 27 24.1 25 6 1 3.2 13 16.5 26 9.3
5 - - - - 3 9.7 - - 1 0.4
3 - - - - - - - - 1 0.4
6A 10 8.9 - - - - - - 4 1.4
19A - - 44 10.4 9 29 - - 27 9.7
2 - - - - - - - - 1 0.4
10A - - - - - - - - 1 0.4
11A - - - - - - - - 1 0.4
15B - - - - - - 2 2.5 3 1.1
33F - - - - - - - - 1 0.4
11 - - 2 0.5 2 6.5 - - - -
15 - - 20 4.8 - - - - - -
Non-typable 8 7.1 - - - - 2 2.5 13 4.7
Others 13 11.6 82 19.5 5 16.2 - - - -
aAll studies were published between 2000 and 2008, and mean score per question was $3.0.
doi:10.1371/journal.pone.0027333.t002
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analysis to provide reasonable confidence intervals.
Twenty-seven percent of patients presenting with pneumonia or
meningitis were colonized by S. pneumoniae. While nasopharyngeal
isolation only indicates colonization and does not identify S.
pneumoniae as the causative agent, a previous case-control study
conducted in Beijing revealed that children with pneumonia were
three times more likely to be colonized by S. pneumoniae in their
nasopharynx compared to controls [34] and therefore may be
helpful in identifying serotypes that are circulating.
Data regarding serotype distribution of S. pneumoniae isolates
were limited to four studies that combined mixed invasive and
non-invasive results. We were unable to disaggregate the serotype
distribution of only invasive isolates, except in one study. Thus, the
serotype coverage of the currently available pneumococcal
conjugate vaccines was based on mixed invasive and non-invasive
isolates. Results from sputum and hypopharyngeal aspirates may
be contaminated from colonizing organisms and certain serotypes
of S. pneumoniae have a propensity for colonization without
necessarily causing disease. However, it is believed that invasive
disease originates from colonization [35] and serotype distribution
of colonization is an indicator of the organisms circulating in the
community. It is important to note that three (19A, 19F and 14) of
the most common serotypes causing invasive disease were also
among the most common serotypes (19F, 19A, 23F, 6A, 6B and
14) seen from mixed specimens. This distribution was consistent
with findings reported by Xue L, et al. and by Xiao SK, et al.,
both from 2010 which included data from different provinces in
China [36,37]. The circulating serotypes were comparable to
those seen in other countries. Serotype 19A is also increasing in
importance especially in countries that have been using PCVs in
their national programs [38,39]. When compared with the
national survey conducted between 1982 and 1985, serotypes 1,
2 and 4 were less frequently isolated [40]. Based on our review, the
currently available conjugate vaccines are expected to cover
79.%–88.4% of circulating serotypes in China. This is an
encouraging finding for policy-makers to accelerate the introduc-
tion of pneumococcal vaccines in China.
Resistance to penicillin and other antibiotics has increased
dramatically worldwide over the past decades due to inappropriate
antibiotic usage [41]. Antibiotic resistance was commonly
observed with beta-lactams and macrolides in Asia. The Asian
Network for Surveillance of Resistant Pathogens (ANSORP)
documented very high prevalence rates (.60%) of erythromycin
resistance among clinical isolates of S. pneumoniae in Taiwan,
Korea, Japan and Vietnam during 1996–1997 [42]. In our review,
data on antimicrobial resistance were from mixed specimens as we
were unable to disaggregate results from invasive isolates only.
Nevertheless, a trend towards increasing resistance to penicillin
Table 3. Antimicrobial resistance
a profile of S. pneumoniae
isolates from both invasive and non-invasive isolates
b.
Antibiotics
No. of
articles
Specimens
tested Resistance
n
Pooled rate
(95%CI)
Erythromycin 21 6371 4349 81.7(66.7–90.8)
Penicillin 20 5746 1059 15.6(8.2–27.7)
Cefuroxime 14 4780 700 19.2(9.4–35.1)
Ceftriaxone 14 4628 450 5.0(1.9–12.7)
Ofloxacin 4 738 36 2.7(0.2–25.9)
Amoxicillin 8 1908 67 3.3(0.7–13.7)
aArticles with mean score per question $3.0 showed similar results. Articles
included in the review used old CLSI breakpoints for Penicillin resistance.
bData cannot be aggregated separately for invasive isolates and are therefore
presented here as mixed with non-invasive isolates.
doi:10.1371/journal.pone.0027333.t003
Table 4. Estimates of pneumonia and meningitis disease burden among children ,5 years of age caused by S. pneumoniae in
2000, China.
Variables Code Value
Parameters
2000 census ,5 yrs A 67,828,891
Incidence of pneumonia B 12815 per 100,000
Mortality of pneumonia C 526 per 100,000
Incidence of meningitis D 14 per 100,000
Case-fatality rate of meningitis E 8.3%
S. pneumoniae isolation rate for pneumonia F 3% (1.3%–6.7%)
S. pneumoniae isolation rate for meningitis G 9.5% (1.2%–47%)
Estimates based on parameters derived from this review
Total cases of pneumonia caused by S. pneumoniae H=B*A*F 260,768 (113,000–582,382)
Total deaths of pneumonia caused by S. pneumoniae I=C*A*F 10,703 (4,638–23,904)
Total cases of meningitis caused by S. pneumoniae J=D*A*G 902 (114–4,463)
Total deaths of meningitis caused by S. pneumoniae K=D*A*E*G 75 (9–370)
Estimates using pneumonia parameters from O’Brien, et al.
S. pneumoniae isolation rate for pneumonia F9 8% (2%–14%)
Total cases of pneumonia caused by S. pneumoniae H=B*A*F9 695,382 (173,845–1,216,918)
Total deaths of pneumonia caused by S. pneumoniae I=C*A*F9 28,542 (7,136–49,949)
doi:10.1371/journal.pone.0027333.t004
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resistance trends had been recently reported. First, pneumococci
resistant to both erythromycin and penicillin had emerged [43].
Currently, 15% to 30% of S. pneumoniae worldwide are multidrug-
resistant (MDR) (i.e., resistant to $3 classes of antibiotics) [44],
narrowing the clinical choice for treatment of PD. Second, only
seven out of .90 serotypes (6A, 6B, 9V, 14, 19A, 19F, 23F) had
been associated with the most resistant isolates [45]. Extensive
usage of the 7-valent PCV has been shown to reduce antibiotic-
resistant IPD in young children and older persons since five (6B,
9V, 14, 19F and 23F) of the resistant serotypes are contained in
the 7-valent PCV. In China, where the 7-valent PCV is available
in the private health setting only and uptake of the vaccine is low,
it is interesting to note that serotype 19A is increasing in some
areas [46]. This suggests that antimicrobial usage may be driving
the circulation of certain antibiotic resistant serotypes in the
community. While reducing antimicrobial pressure through
stricter prescription policies has been initiated in China and will
control circulation of antibiotic-resistant causing pneumococcus,
use of the 19A-containing 13-valent PCV will likely substantially
reduce PD in children.
The absence of population-based IPD surveillance studies in the
past three decades in China has precluded us from providing more
accurate point estimates of PD burden, however, based on our
analysis S. pneumoniae-associated disease remains to be one of the
leading causes of childhood deaths in China. With increasing
antibiotic resistance and emergence of multidrug-resistant bacte-
rial strains, introducing pneumococcal vaccines into the routine
immunization program should be considered in China. Popula-
tion-based studies are clearly warranted.
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